These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30664338)

  • 21. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sexual Dysfunction in Patients with Antidepressant-treated Anxiety or Depressive Disorders: a Pragmatic Multivariable Longitudinal Study.
    Preeti S; Jayaram SD; Chittaranjan A
    East Asian Arch Psychiatry; 2018 Mar; 28(1):9-16. PubMed ID: 29588433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.
    Thase ME; Fayyad R; Cheng RF; Guico-Pabia CJ; Sporn J; Boucher M; Tourian KA
    Curr Med Res Opin; 2015 Apr; 31(4):809-20. PubMed ID: 25758058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.
    Yılmaz R; Üstün D; Tuncer Uzun S; Reisli R; Türk Ş
    Agri; 2018 Oct; 30(4):199-201. PubMed ID: 30403275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Keeping up with the clinical advances: tardive dyskinesia.
    Elkurd MT; Bahroo L
    CNS Spectr; 2019 Aug; 24(S1):70-81. PubMed ID: 31482777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.
    Fava GA; Benasi G; Lucente M; Offidani E; Cosci F; Guidi J
    Psychother Psychosom; 2018; 87(4):195-203. PubMed ID: 30016772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs: Etravirine, sinecatechins, and desvenlafaxine succinate.
    Hussar DA; Campoli KE
    J Am Pharm Assoc (2003); 2008; 48(3):428-31. PubMed ID: 18595832
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.
    Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C
    J Affect Disord; 2016 Oct; 203():55-61. PubMed ID: 27280963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine.
    Sarfati D; Evans VC; Tam EM; Woo C; Iverson GL; Yatham LN; Lam RW
    Int Clin Psychopharmacol; 2017 Nov; 32(6):343-349. PubMed ID: 28763344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Desvenlafaxine-induced worsening of hypertension.
    Munoli RN; Praharaj SK; Bhandary RP; Selvaraj AG
    J Neuropsychiatry Clin Neurosci; 2013; 25(2):E29-30. PubMed ID: 23686052
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
    Kornstein SG; Guico-Pabia CJ; Fayyad RS
    Hum Psychopharmacol; 2014 Sep; 29(5):492-501. PubMed ID: 25196042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New-onset psychosis following initiation of eye movement desensitization and reprocessing therapy.
    White M; Doty M
    Ann Clin Psychiatry; 2020 May; 32(2):142-143. PubMed ID: 32343285
    [No Abstract]   [Full Text] [Related]  

  • 36. Inconsistent portrayal of medication dependence, withdrawal and discontinuation symptoms in treatment guidelines for anxiety disorders.
    Starcevic V; Brakoulias V; Viswasam K; Berle D
    Psychother Psychosom; 2015; 84(6):379-80. PubMed ID: 26402919
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duloxetine-related tardive dystonia and tardive dyskinesia: a case report.
    Chen PY; Lin PY; Tien SC; Chang YY; Lee Y
    Gen Hosp Psychiatry; 2010; 32(6):646.e9-646.e11. PubMed ID: 21112461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo.
    Clayton AH; Reddy S; Focht K; Musgnung J; Fayyad R
    J Sex Med; 2013 Mar; 10(3):768-76. PubMed ID: 22905811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.